<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-011141
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050412
<FILING-DATE>20050412
<DATE-OF-FILING-DATE-CHANGE>20050412
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05745129
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v016134_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of April 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission
File Number 000-5112</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff
border=0>
  <TR vAlign=top bgColor=#ffffff>
    <TD width="50%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="49%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2><FONT face="Times New Roman" size=2>pSivida
  Limited</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>Date:&nbsp;April 12,
2005</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>/s/&nbsp;Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
    <TD align=left>
      <HR align=left width="80%" color=#000000 noShade SIZE=2>
      <FONT size=2>Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2><EM>Chief Financial Officer and
      Company Secretary</EM></FONT></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT size=2></FONT>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="85%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Top
      5 Global Pharmaceutical Company: Significant Progress in
      BioSilicon</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>TM
      </SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Drug
      Delivery Evaluation</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>&nbsp;</SUP></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="15%">&nbsp;</TD>
    <TD vAlign=top align=left width="85%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v016134_ex99-1.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left>&nbsp;</DIV>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>
  <TR bgColor=#ffffff>
    <TD width="50%">&nbsp;</TD>
    <TD width="50%">
      <DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
      align=right><IMG SRC="logo.jpg"><FONT id=TAB2
      style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</DIV></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><STRONG><FONT size=2>ASX/MEDIA
      RELEASE</FONT></STRONG><FONT id=TAB2
      style="COLOR: black; LETTER-SPACING: 161.1pt">&nbsp;</FONT></TD>
    <TD width="50%">
      <DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
      align=right><STRONG><FONT size=2>12<FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      April 2005</FONT></FONT></STRONG></DIV></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><STRONG>Top
5 Global Pharmaceutical Company:<BR>Significant Progress in
BioSilicon</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM</STRONG></SUP></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><STRONG>Drug
Delivery Evaluation</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<DIV>
<HR align=center width="100%" color=#000000 noShade SIZE=1>
</DIV>
<DIV>&nbsp;</DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
nanotechnology company pSivida Limited </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>(ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is
pleased to announce that its evaluation of selected compounds from an
undisclosed top five global pharmaceutical company has progressed successfully.
The collaboration agreement was signed at the end of December 2004, and covers a
staged evaluation of the pharmaceutical company&#8217;s proprietary compounds in
pSivida&#8217;s porous silicon, controlled release platform (BioSilicon</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">). The
initial stage of the planned 12-month programme has concluded meeting the agreed
technical success criteria, and in turn triggering the next payment to pSivida
under the terms of the agreement. More advanced assessment of the first compound
will continue, whilst a second compound will enter the planned technical
evaluation.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
Managing Director, Mr Gavin Rezos said, &#8220;We are delighted with the rapid
progress which has been made in meeting this first milestone in the programme.
The work has been conducted in the laboratories of our UK operating subsidiary,
pSiMedica Ltd, and supports the efficiency and expertise of our scientists.
Importantly, the data also provides further validation of our technology
platform in leveraging the drug delivery of proprietary therapeutics.&#8221;
</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Released
by:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      Australia:</STRONG></FONT></DIV></TD>
    <TD vAlign=top width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      US:</STRONG></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Josh
      Mann, CFA</FONT></DIV></TD>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
      Jedynak</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
      Relations</FONT></DIV></TD>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited</FONT></DIV></TD>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
      E. Janis &amp; Company, Inc.</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      + 61 8 9226 5099</FONT></DIV></TD>
    <TD vAlign=top align=left width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      312-943-1100 ext. 12</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>joshuamann@psivida.com</U></FONT></DIV></TD>
    <TD vAlign=top width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>bjedynak@janispr.com</U></FONT></DIV></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV><BR>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
TO EDITORS:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products in healthcare. The company&#8217;s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
biocompatible material, BioSilicon&#8482; offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
animals. The IP portfolio consists of 24 patent families, 26 granted patents and
over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is listed on NASDAQ (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
Australian Stock Exchange (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For more
information on QinetiQ visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.qinetiq.com</U></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
information visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.psivida.com</U></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif">This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including: our
failure to develop applications for BioSilicon(TM)</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"> due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration Statement on Form 20-F filed with the
U.S. Securities and Exchange Commission, including, without limitation, under
Item&nbsp;3.D, "Risk Factors" therein. We do not undertake to update any oral or
written forward-looking statements that may be made by or on behalf of
pSivida.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV></DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0JX17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C`T.C$Q(#(Q.C$S
M.C0P``````.@`0`#`````?__``"@`@`$`````0```+2@`P`$`````0```#D`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)B@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"D`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DEF9EMF'DLM98XUN</5K<[<(<=OL#G>S9^;L8H>8
MSC#$3D+A8$B/T0?TD@7HZ:I=3ZQ@],8W[0XNNMD48M0-E]KA^9CX[/?9_P">
MZ_\`"OK8JG5KK<>T&G(?N>27UR"&Z>SVQ[=VUZF0,;"_:'\[F6UL8VUX:7`/
M(=Z;7AH?Z6[])Z:@^_Q&7-CE"0]B/N9)>FN#AXX\/]Y1B2`01KHB&-USJ0=9
MGWGI&+KMQ<5S3?MT]V7G.%E=?'\UA-_1_P#<RY/]5+,NWI(NON?D566VNPK;
MOYUV+O(Q'W.AN]UE7Z5C_P#165HCNFNSL/[/=<]U%YC+EQ)L8TG]79#GMJKR
M/^U&S_`_H?\`";ZM&RVC&I-EKV4TUCW/<0UC1QJYT-:K6*9GCC(CAXAQ<.]6
MLX:D3>W4]4B2JGJG31934<NCU,EH?CL]1FZQKOH/I;NW6M?^;L0NIYMU#JJ,
M<#UKC`)[:[1_G.*;GS0PXSDG="M(BY2,O3&,0NCZC0;Z2S<;)ZA5F#%RV^H'
MB18P<>?M`]J.\7?M!A%[15MUQY]Q,.]VU1PYN,XB0A,'W!BE"8X)PD?WO_0$
MF-?9;;20:,S$R7V,Q[Z[GTG;:VM[7%ADC;8&D['>QWTEG=7RVYO1LH]*ZG1C
MVMVM&9ZC2RIVYA<+'MWM9O9[/[:LK#(`7OO^#KI+/Z58^CHV/9G9E>2ZNH.O
MS0X>FZ![KO4]K-G\I8W7_K'D4]3Z$SI6359A]1R#5>]FVUK@+,>LM9:TG;_.
MV?12I$L@C'B/AI_>>I20,K-P\-@LS+Z\9CC`?:]K`3X;K"U2Q\G&RJA=C6LO
MJ=Q96X/:8\'LEJ2ZQ=7J_P#_T/55E=8LH=<S%%C?M3JW6MHU+BRMS-UGIL:]
MVS>_8K75.HT=+Z?=GW@N92V0Q@ESW$AE5-;?])=:YE5?\M5>A=,R,=EF?U$A
M_5L_:_+<-6U@?S.#1_W7Q&NV?\-;ZN1_A5%S&&.;%+'+02%*$B)"O,N597A,
MK<_'-CLG)M??F/N)-CGGVUM+X#?2HK_08U;/YJE7K,IF3C8V'2'.<T,-I#70
M-@^AHUWYWYRE]9+:ZF8YL=&YSFL:`7/<X@;:ZJF_I+;'?N,6ATXW'#J]5@K(
M8T!DAQ``_/<S=7N_J?\`;BR8<KGR<WS,9Y!PRCCADR^W7N\,87"'K],N'^<7
M\41&(`[FNR:BLUTM8=2.>^IU\&K(^NH!^JO40=1Z7_?FK;6)]=?_`!+=1_XK
M_OS5M0B(B,1M&@/HQ9?DG_=+PG5^DX&/]1NF]7IKV=0LL9OR))>1MMVMU/M;
M5Z-7H_Z'9[%Z/EX1S\>JUKO3O:T.:[MJ`[;HN"_9OUFZU]6NE=)HQ*C@$BUN
M<VP>UOZ2O9D4V;'L?3ZCWO\`1];UOT?I_GKN^H8-[C3=B'WT0`PG0@?1(GVJ
M'G@)8)`XCG'7'$U.N+YH?UH?,Q<J*D2/2#&&M;RX6&'GY560,+.'O.C+/^IG
M]_=^^E=_R_1_Q9_)8HU8N?E9M>3EL%3:8(:"-2-1W=^<CV8U[NKU9`;^A:PA
MSY',/_-^E^<LZ$<\L4!(9)PAS6(XCEC^N]B,M99/ZL?WVWI9V^4W7=Y!]QZ!
M];/K`6?HV96!9FTS^=:T;_\`S^[)0<?I[</_`!5Y#BV'Y<9#P1^];577_P"`
MU5+0^O\`]6>I]6OQ,KI='K6M8^F_WL9#9:^EWZ5S-VUSKEK_`%AZ/?;]4[>D
M=.K]6QE555%9<ULBMU7Y]A:S^;K6U>S1,)7E%&A&7!X^Y^Z\OU^U]7^+/I;&
M':VWT&/`X+0VR[:?^N5,2ZST7IO2NL?5?[#2*3??7ZQ!/O<Q^+ML>WZ/J_I'
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M;96YIK>[?=98:F;G7,K_`$OL]9N]+HN`)S`\)%2E>G2OFXW_T>V^LN?TW&R,
M!G51=7BLM;E4Y%;'65^M3]#'R&4LM?[O4]:G^73_`,&G_;G5NI'9T3I[V5GG
MJ'4&NIJ`_>IQ/;F97M_DXU?_``RWDD6/6S1/C0]3CT?5YK9NR<NW*SK&[;LM
M^T.+>]-%8'IXF-_P-'\Y_P!J++UI8N.<=GI^JZQ@`#`X-]H'8;&M1DE6_4_>
M#O[_``_ZS^;_`/2?!_W;)'Y=/E_:I4^K=-JZKTZ_I]SW5UY#=KGLC<!(=[=X
M>WLKB2L(E5&]JU\FITGIM72^G4=/I>ZRO';M:]\;B)+O=L#&]U;2225&J%;5
MIY*22222I))))2DDDDE*22224__9_^T/<E!H;W1O<VAO<"`S+C``.$))300E
M```````0`````````````````````#A"24T#[0``````$`!(`````0`!`$@`
M```!``$X0DE-!"8```````X`````````````/X```#A"24T$#0``````!```
M`'@X0DE-!!D```````0````>.$))30/S```````)```````````!`#A"24T$
M"@```````0``.$))32<0```````*``$``````````3A"24T#]0``````2``O
M9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````
M!@```````0`U`````0`M````!@```````3A"24T#^```````<```________
M_____________________P/H`````/____________________________\#
MZ`````#_____________________________`^@`````________________
M_____________P/H```X0DE-!`````````(``3A"24T$`@``````!``````X
M0DE-!`@``````!`````!```"0````D``````.$))300>```````$`````#A"
M24T$&@`````#20````8``````````````#D```"T````"@!5`&X`=`!I`'0`
M;`!E`&0`+0`Q`````0`````````````````````````!``````````````"T
M````.0`````````````````````!`````````````````````````!`````!
M````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M````.0````!29VAT;&]N9P```+0````&<VQI8V5S5FQ,<P````%/8FIC````
M`0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)
M1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U
M=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@
M````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`
M`````````$QE9G1L;VYG``````````!"=&]M;&]N9P```#D`````4F=H=&QO
M;F<```"T`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````
M37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X
M=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI
M9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!
M;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#
M;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)
M=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O
M='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))
M3001```````!`0`X0DE-!!0```````0````".$))300,``````FF`````0``
M`(`````I```!@```/8````F*`!@``?_8_^``$$I&248``0(!`$@`2```_^T`
M#$%D;V)E7T--``+_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``I`(`#`2(``A$!`Q$!
M_]T`!``(_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))9F9;9AY++66.-;G#U:W.W
M"'';[`YWLV?F[&*'F,XPQ$Y"X6!(C]$'])(%Z.FJ74^L8/3&-^T.+KK9%&+4
M#9?:X?F8^.SWV?\`GNO_``KZV*IU:ZW'M!IR'[GDE]<@ANGL]L>W=M>ID#&P
MOVA_.YEM;&-M>&EP#R'>FUX:'^EN_2>FH/O\1ES8Y0D/8C[F27IK@X>./#_>
M48D@$$:Z(AC=<ZD'69]YZ1BZ[<7%<TW[=/=EYSA977Q_-83?T?\`W,N3_52S
M+MZ2+K[GY%5EMKL*V[^==B[R,1]SH;O=95^E8_\`T5E:([IKL[#^SW7/=1>8
MRY<2;&-)_5V0Y[:J\C_M1L_P/Z'_``F^K1LMHQJ39:]E--8]SW$-8T<:N=#6
MJUBF9XXR(X>(<7#O5K.&I$WMU/5(DJIZITT64U'+H]3):'X[/49NL:[Z#Z6[
MMUK7_F[$+J>;=0ZJC'`]:XP">VNT?YSBFY\T,.,Y)W0K2(N4C+TQC$+H^HT&
M^DLW&R>H59@Q<MOJ!XD6,''G[0/:CO%W[081>T5;=<>?<3#O=M4<.;C.(D(3
M!]P8I0F."<)'][_T!)C7V6VTD&C,Q,E]C,>^NY])VVMK>UQ89(VV!I.QWL=]
M)9W5\MN;T;*/2NIT8]K=K1F>HTLJ=N87"Q[=[6;V>S^VK*PR`%[[_@ZZ2S^E
M6/HZ-CV9V97DNKJ#K\T.'IN@>Z[U/:S9_*6-U_ZQY%/4^A,Z5DU68?4<@U7O
M9MM:X"S'K+66M)V_SMGT4J1+((QXCX:?WGJ4D#*S</#8+,R^O&8XP'VO:P$^
M&ZPM4L?)QLJH78UK+ZG<65N#VF/![):DNL75ZO\`_]#U5976+*'7,Q18W[4Z
MMUK:-2XLK<S=9Z;&O=LWOV*UU3J-'2^GW9]X+F4MD,8)<]Q(9536W_276N95
M7_+57H73,C'99G]1(?U;/VORW#5M8'\S@T?]U\1KMG_#6^KD?X51<QACFQ2Q
MRT$A2A(B0KS+E65X3*W/QS8[)R;7WYC[B38YY]M;2^`WTJ*_T&-6S^:I5ZS*
M9DXV-ATASG-##:0UT#8/H:-=^=^<I?62VNIF.;'1N<YK&@%SW.(&VNJIOZ2V
MQW[C%H=.-QPZO58*R&-`9(<0`/SW,W5[OZG_`&XLF'*Y\G-\S&>0<,HXX9,O
MMU[O#&%PAZ_3+A_G%_%$1B`.YKLFHK-=+6'4CGOJ=?!JR/KJ`?JKU$'4>E_W
MYJVUB?77_P`2W4?^*_[\U;4(B(C$;1H#Z,67Y)_W2\)U?I.!C_4;IO5Z:]G4
M++&;\B27D;;=K=3[6U>C5Z/^AV>Q>CY>$<_'JM:[T[VM#FN[:@.VZ+@OV;]9
MNM?5KI72:,2HX!(M;G-L'M;^DKV9%-FQ['T^H][_`$?6];]'Z?YZ[OJ&#>XT
MW8A]]$`,)T('T2)]JAYX"6"0.(YQUQQ-3KB^:']:'S,7*BI$CT@QAK6\N%AA
MY^55D#"SA[SHRS_J9_?W?OI7?\OT?\6?R6*-6+GY6;7DY;!4VF"&@C4C4=W?
MG(]F->[J]60&_H6L(<^1S#_S?I?G+.A'/+%`2&2<(<UB.(Y8_KO8C+663^K'
M]]MZ6=OE-UW>0?<>@?6SZP%GZ-F5@69M,_G6M&__`,_NR4''Z>W#_P`5>0XM
MA^7&0\$?O6U5U_\`@-52T/K_`/5GJ?5K\3*Z71ZUK6/IO][&0V6OI=^E<S=M
M<ZY:_P!8>CWV_5.WI'3J_5L9555167-;(K=5^?86L_FZUM7LT3"5Y11H1EP>
M/N?NO+]?M?5_BSZ6QAVMM]!CP."T-LNVG_KE3$NL]%Z;TKK'U7^PTBDWWU^L
M03[W,?B[;'M^CZOZ1V]_YZU.I_5GJ6;]1</I8KV]0Q&U/]`N;JY@=795ZN[T
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MKYN-_]'MOK+G]-QLC`9U475XK+6Y5.16QUE?K4_0Q\AE++7^[U/6I_ET_P#!
MI_VYU;J1V=$Z>]E9YZAU!KJ:@/WJ<3VYF5[?Y.-7_P`,MY)%CULT3XT/4X]'
MU>:V;LG+MRLZQNV[+?M#BWO316!Z>)C?\#1_.?\`:BR]:6+CG'9Z?JNL8``P
M.#?:!V&QK49)5OU/W@[^_P`/^L_F_P#TGP?]VR1^73Y?VJ5/JW3:NJ].OZ?<
M]U=>0W:Y[(W`2'>W>'M[*XDK")51O:M?)J=)Z;5TOIU'3Z7NLKQV[6O?&XB2
M[W;`QO=6TDDE1JA6U:>2DDDDDJ22224I))))2DDDDE/_V3A"24T$(0``````
M50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`.$))
M300&```````'``$````!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E
M4WI.5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*
M/'@Z>&%P;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T:STG
M6$U0('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F.E)$
M1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8
M+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z9C9D9F,X
M-S@M86%E9BTQ,60Y+3@Q9&(M969D-SDQ8V5D8V4R)PH@('AM;&YS.GAA<$U-
M/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ
M1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z9C9D9F,X-S8M86%E
M9BTQ,60Y+3@Q9&(M969D-SDQ8V5D8V4R/"]X87!-33I$;V-U;65N=$E$/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M/#]X<&%C:V5T(&5N9#TG=R<_/O_N``Y!9&]B90!D@`````'_VP"$``P("`@)
M"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,
M#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`#D`M`,!
M(@`"$0$#$0'_W0`$``S_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)
M"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%
M`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!
M``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DD+(N?2S>RLV
MF8+6QH/WM4V4A&)D=AO0XOPBI*DJ^+FU9.X-EKV:/8[D(-O5L>EQ;8RQL$B2
MW0Q^[JHI<W@C`9#DB(2VET3PFZIO*EU/K&!TNH69=D.>8JJ:-UCS^Y54WWO0
M;.I.RJG58+G57OAK;G5^HUA/YSF![%6QNFX'2+ADY#GY_5;M'9-D&P^5;?H8
M]/\`(8E'F^7.,Y!DB81T,@MD)WPQ&_Z1_@LT_6;J@WM+>BXQ^BUS1=DD?RP[
M]!1_5_2/2^KF7U)^9U/!S+_ME>#:QE626ACB7-WV5O%?L_1>U7,WJ615AS30
M?MM[O2Q:'=WD?SCX_P`#5_.6N_<1.C],9TS";CAQMM<39D7'FRUYW6VN_K.4
M\9B41(;2VTX?^DQ\)$QJ3P_.;T\(\/R-U))))E4DHO>QC2]Y#6CDG0*NWJ>`
MYVT7"?.0/\XA1SS8L9`GDC`RV$I1C?\`C)`)V#:23<ZA5Z^H469)QF[O4:2#
M(T]O*,\L(&(E(1,SPPO]*7[H51;*222>A22S.N?6'`Z'759F^H6W.+6>FW=J
M!NUU:KN)DUY>+3E53Z=[&V,W"#M<-S=P20)1,C&_4-PF23.<UK2YQAK1)/D%
M2Z=UKI74W/;@9+,@U`%X;.@/T>1Y)*L`@$BSLWDDDDDJ22224__0]547B6.'
MB"I))$6*4X>*\,ZG46$18"UP!9'!_P!#[5#J74L3.WUXK_4^R6^E:\?1WENX
ML8[\[9^>FS#6VT6-L;8UCG,.UY<2/H6,W;=K+&?UD.]G3*.GXV)TX!E5,^R#
M.H^D^?I/=^<Y<[/)''R?.\O.0&3C$XPD:D1+V^+A_P`5D]1G`BN&C9_)T.@_
MT>S^O_`*O>X/ZE<7D>V&M!+/_1WM3]*S<?%Q[/5=#BZ0T"2=$L!C\G(?<#]-
MVYX#B"!/'T-KO\Y*$XY>6Y+EX2!GQ&<HQ/JCP\?#Q?XR[:4BZXIK%GJQ[]NT
M'P;^ZU$2271,+@6_7;H=.=DX5[K*GXF_U'N:-I+#MVUPXO>YT^SV*'1_KST?
MJV:,*H6TVOGTC:``^-=H+7/VN7,=-QZ,C_&/D5WUMM8+KW;7B1+0XM.T_NI?
M6:FK#^O>&_&:*][\>PAH@;B_8XZ?O-:G\(V\&E[^6N.QPC)[9%:T]CU^QX]*
ML?1,N/F0D>D4V83;,<EUI:"#.A/YS5H9N'7EU;'^UPU8X=BL8C/Z79(/Z,GX
ML=_Y%<]SV$8^9RYN8Q'-R^:,8^Y'6?+:<+I1-Q`!HC\77Z=3D48PJO():?;!
MF!^ZA4VX!SW,KK(R`7;GQI/YW=6,/*9ET"UH@\.;X%9>)_RW9_6L5K+DACCR
M,<59,<\D(1ED'N2X.\9?HS6@7Q7IHR?]:NFLZV.AO;:W++@P.+1L)+?4;[]W
MYS?Y*?KOUHZ;T)]->8+'/O!<P5-#M&P/=N<S]Y<K]?JW=/\`K#T[K%8B=I<?
MY5+P[_SV]1Z_'6?KYAX0.^FD5!T<;0/M=O\`T'+6X1IY-&6>8XXZ<8G&,/[L
M_E>C^M6;]7Z,7%LZYBOR*['$TL#9+7;9=N][/S5JX61A-Z51DTCT,(4-LK#M
M-E0;N;N^E]"M<G_C1_H6!_QK_P#J0KW4GN9_B[!:8)PJ6_)PJ8[\J5:#S7>X
M1ERZ#T0XMO5]K%O^,+H&4^W%FVD/:YM=UC0&$P8^BYSV;OY;5D_XK?Z1U#^I
M5^6Q6OJ+T[!O^J^99?0RUUMEC7E[0=&L;L;K^ZJO^*W^D=0_J5?EL1THTQ1E
M.63EY3(/%Q$5Y/2]<^N/1^BW?9KR^[(`!=54`2T'CU'.+&M3=#^N72.M7_9J
M-].1!<VNT`;@/I>FYKGM<LWJ'1_JOT7JC^L]6RG6W7.?8W&MVO!<[]REK-[O
M3_,W+F<7-PLOZ\8N5TZHXV-;D5[*R`WD;+';&>UOJ(``A=//DA,68ZRX?;'S
M</[SZLDDDFMQ_]'U58?U@ZGE&VKHG2W1U+-!+K.U%/%F2_\`E?Z);%]K:*++
MG_1J:7NCP:-RQ/JEBV68UG6\P3F]5/JDG\RG_M-0S^1Z?N1'=CF22(#3BW/:
M#I=-Z3A=.P&8-+`ZMFKBX27O/T[;/WGO5+K6-12RMU5887.,P([+8>]K&E[R
M&M:)<XF`!YE<YU+JK.JQ7TPAU%+CZN>\'T0?W*.'9=W_`!?Z+_A51^)8!EY;
M+48\="ISX8\'JU/'+Y62$HP,1]D1_P!ZVND58CZW>LQK["Z&`B3``_-_=6RU
MC&#:P!H\`("R.@#$HK>T._2N<`;+"/4?IR[_`+[77^C8ME#X9#%'EL?MF,R!
M4IQ%<7J_Q_\`'72,B3>G@I)))7EKYCC=0Q.F_P",'*RLQ_IT"^YKGP2!N#F-
MW1^;N3]8S<?K7UXPW8#_`%JFV45BQO!V.]6QS?Y+$3IE--_^,7+IN8VRI]F2
M'L<`01M=RTKM>G?5GH?3,DY6%BMJN,@/ESH!Y%>]SMG]E/)`^QH8\4\D2`0(
M>Z92_>T7ZQ=F4;'TO+:CHZ`-'?%"RNJXU^"ZN#ZKQ!;&@/[VY:SV,>TL>`YI
MY!U"K#I6`';O2'P),?=*RN9Y3G#DRG!EC[>>/!.&;BE[?Z/ZITA*-"QMV:_0
MJWMQWO=HU[O;\NZKXG_+=G]:Q;0`:``(`X`0FXF,RXWM8!:9)=KWY1/P^0Q\
MI"$@1RTQ.1E^G^E+A5QZR/[P><_QBX/VGH'VAHEV)8VR?Y+OT3_^K:L'_%SC
MVYG6<GJ5Y+S14&;S^\_V-_\``JG+T+)QJ,O'LQLA@LIM&VQAX(*!TWI'3>EL
M?7T^AM#;"'/#23)`C\XN6F):4U)8.+/')?I&X_K#Y7D_\:/]"P/^-?\`]2%H
M9U+[_P#%Z&5@N=]AJ=`\&-KL=_T6+<ZET?IO56,9U"AM[:B7,#B1!.A^@6JQ
M3CTT8[,:I@;36T5L9R`T#:&Z_P`E"]!X)]DG)DD2*R1X?%X#ZF_6+I6!]7LK
M$S+A7<'O=77!+GA[6M;Z8;])V]J?_%;ID=0!_<J_+8NKQ?JG]7L3+^V483&W
M`[FDESFM/BRM[G5L_P`U6>G=$Z5TM]C\#';0ZZ/4+2XS$D?3<[]Y$D:^*S'@
MR"6(R,:Q6-.Q?.>D9G3,SZTY.9]9+!M:7FMMLEF]KMK*GC]RMGT&*;NH8?4?
MK]BY6%_1C?2RLQM!#`VN6M_<]OM7<Y7U1^KV9ENS,C#:ZYYW/(+FAQ_>>QCF
ML<C?\W.A_:Z\T8;&Y%.WTGMENW9_-[6M(9[?ZJ/$/P6CELE5<=)\=Z\<O[SI
M))))C<?_TO0OK!E9^'ALRL+'.8:K`;\=OTGU$.99LY]S=S7+*H^LO4[ZF8_2
M.A9#2T!K3D134P#0"?W6KJ$D0PSXN(\)EM^B(?\`-XWG*_JYU'J;Q=]9,OUZ
MP9;T_'EE`_XT_3O6X,+$#&5BE@96-K&AHAH_=:W\U'23,O!P_K.'@_K5P?\`
M.78N'7AOB_2XOYSZH6XF*UP<VE@<#((:)!1DDDW'[5'VN&NOM\/_`'+*;ZJ2
M224B&LSIO3Z\DY;,:IN2XDF\,:'DN^E^DC?[E92220*Z5]%)))))4DDDDI22
6222E))))*4DDDDI22222E))))*?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
